Literature DB >> 18926775

Modulation of the cellular immune system by intravenous immunoglobulin.

Thanyalak Tha-In1, Jagadeesh Bayry, Herold J Metselaar, Srini V Kaveri, Jaap Kwekkeboom.   

Abstract

Intravenous immunoglobulin (IVIg) is therapeutically used in a variety of immune-mediated diseases. The beneficial effects of IVIg in auto-antibody-mediated diseases can be explained by neutralization, accelerated clearance and prevention of Fcgamma-receptor binding of auto-antibodies. However, the means by which IVIg exerts therapeutic effects in disorders mediated by cellular immunity have remained enigmatic. Clinical improvements, followed by IVIg treatment, often extend beyond the half-life of infused IgG, thereby indicating that IVIg modifies the cellular immune compartment for a prolonged period. Here, we discuss recent advances in the understanding of different, mutually non-exclusive mechanisms of action of IVIg on cells of the innate and adaptive immune system. These mechanisms might explain the beneficial effects of IVIg in certain autoimmune and inflammatory diseases.

Mesh:

Substances:

Year:  2008        PMID: 18926775     DOI: 10.1016/j.it.2008.08.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  61 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.

Authors:  Mohan S Maddur; Shivashankar Othy; Pushpa Hegde; Janakiraman Vani; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 3.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

4.  Normal IgG downregulates the intracellular superoxide level and attenuates migration and permeability in human aortic endothelial cells isolated from a hypertensive patient.

Authors:  Xiuqing Wang; Qianyu Wang; Zhongjie Sun
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

Review 5.  Polyvalent immunoglobulins: challenges and perspectives.

Authors:  Isabella Quinti; Serelina Coluzzi; Federica Pulvirenti; Alessandro Prezzo; Gabriella Girelli
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

6.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

7.  sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion.

Authors:  Massimo Ghio; Paola Contini; Maurizio Setti; Gianluca Ubezio; Clemente Mazzei; Gino Tripodi
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

Review 8.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

9.  FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.

Authors:  Sudhir Gupta; Sudhanshu Agrawal; Sastry Gollapudi; Hiromi Kubagawa
Journal:  Hum Immunol       Date:  2016-10-14       Impact factor: 2.850

10.  Optimization of immunoglobulin substitution therapy by a stochastic immune response model.

Authors:  Marc Thilo Figge
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.